Register for our free email digests:
Intercept Pharmaceuticals Inc.
www.interceptpharma.com
Latest From Intercept Pharmaceuticals Inc.
Zydus Cadila Strides Ahead With NASH Filing In India
Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.
Keeping Track: Oxbryta Approval Headlines Pre-Thanksgiving Week Of News
The latest drug development news and highlights from our US FDA Performance Tracker.
CymaBay Shelves NASH Drug Seladelpar On Liver Safety Concerns
Atypical histological findings from a Phase IIb NASH study lead CymaBay to terminate mid-stage studies in NASH and PSC and place a Phase III PBC trial on hold.
Galectin’s NASH Phase III Trial Will Use Surrogate Measures Of Esophageal Varices
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Therapeutic Areas
- Hepatic (Liver)
- Metabolic Disorders
- Alias(es)
- Ownership
- Public
- Headquarters
-
Worldwide
-
North America
-
USA
-
USA
-
North America
- Parent & Subsidiaries
- Intercept Pharmaceuticals Inc.
- Senior Management
-
Mark Pruzanski , MD, Pres. & CEO
Sandip Kapadia, CFO
David Shapiro, MD, CMO
Jerome Durso, COO
Jason Campagna, MD, PhD, CMO - Contact Info
-
Intercept Pharmaceuticals Inc.
Phone: (646) 747-1000
10 Hudson Yards
37th Fl.
New York, NY 10001
USA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice